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Abstract: Introduction: Although electronic cigarettes (e-cigarettes) and other tobacco-related
products are becoming widely popular as alternatives to tobacco, little has been published on the
knowledge of healthcare workers about their use. Thus, the aim of this study was to elicit the current
knowledge and perceptions about e-cigarettes and tobacco harm reduction (THR) among medical
residents in public health (MRPH). Material and Methods: A Europe-wide cross-sectional study was
carried out amongst MRPH from the countries associated with the European Network of MRPH from
April to October 2018 using an online questionnaire. Results: 256 MRPHs agreed to participate in the
survey. Approximately half the participants were women (57.4%), with a median age of 30 years, and
were mainly Italian (26.7%), Spanish (16.9%) and Portuguese (16.5%). Smoking prevalence was 12.9%.
Overall, risk scores significantly differed for each investigated smoking product when compared
with e-cigarettes; with tobacco cigarettes and snus perceived as more risky, and nicotine replacement
therapy (NRT) and non-NRT oral medications seen as less risky (p < 0.01 for all). Regarding the
effects of nicotine on health, the vast majority of MRPHs associated nicotine with all smoking-related
diseases. Knowledge of THR was low throughout the whole sample. Conclusions: European MRPH
showed a suboptimal level of knowledge about e-cigarettes and THR. Training programs for public
health and preventive medicine trainees should address this gap.
Keywords: electronic cigarettes; harm reduction; healthcare workers; nicotine; public health;
smoking cessation
1. Introduction
Recent data on the global tobacco epidemic published by the World Health Organization declared
that, with over 1.1 billion smokers, tobacco remains the leading single preventable cause of death
worldwide, killing over 7 million people each year and being responsible for one in ten deaths [1,2].
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In recent years, electronic cigarettes (e-cigarettes) and the use of other tobacco-related products
have become widely popular and have been extensively highlighted as alternatives to smoking or
aids for smoking cessation [3,4], addressing potential challenges concerning tobacco morbidity and
mortality [5].
E-cigarettes are battery-operated electronic devices that, instead of burning tobacco, produce
vapors containing, amongst others, nicotine, propylene glycol and chemical additives [6,7]. Doubts
remain around their safety and the United States Food and Drug Administration (FDA) warns that
e-cigarettes still contain several toxic chemicals and suspected carcinogens that may be harmful to
human health [8,9]. Indeed, the debate around the potential health impacts of e-cigarettes is ongoing
within the scientific community, and across European countries, current policies and regulatory
strategies surrounding e-cigarette use remain uncoordinated [10–12].
Similarly, little attention has been paid to investigating the knowledge of healthcare workers
toward the use of e-cigarettes and tobacco harm reduction (THR) strategies, particularly in the public
health field, although the evidence available thus far suggests a suboptimal level of awareness [13,14].
Tobacco is a public health priority and public health professionals have an important role in
providing interventions for smoking cessation and prevention, both with individual therapeutic
actions and from a population perspective [15]. For this reason, educational and training programs
for future public health professionals should be consistent with the latest evidence-based approaches
against the tobacco epidemic [14,15]. The licensing and marketing of alternative forms of smoking
habits and nicotine utilization amongst users—such as e-cigarettes and THR—requires that curricular
pathways for future public health professionals have to parallel the epidemiological transition of
smokers’ behaviors, in order to better tackle the tobacco threat and promote healthy lifestyles. In this
frame, it has been also recognized that smokers who want to quit or shift to other nicotine products are
often poorly helped by public health authorities [16,17].
THR refers to a public health strategy that aims to reduce the health risks associated with tobacco
smoking. Since the 1970s, when the late psychiatrist Russell famously stated that, “smokers smoke for the
nicotine, but die from the tar”, THR has been a long-standing issue. Accumulating evidence suggests that
safer nicotine alternatives may garner considerable public health benefits and reduce the morbidity
and mortality caused by smoking [18–20]. As early as 2003, the WHO Framework Convention on
Tobacco Control acknowledged the utility of this strategy by including THR in tobacco control policies,
due to its important role in eliminating or reducing population consumption of tobacco products and
exposure to tobacco smoke [17,21]. Moreover, results from practical experience have suggested an
emerging optimism (for instance, with the general public preference for e-cigarettes worldwide, and
snus use in Sweden), despite divided opinions [22]. Yet, 40 years from the conception of THR, it still
raises many controversial questions, mainly due to inconclusive findings regarding the actual potential
danger of THR tools and devices and the need for further prospective clinical research in order to
highlight the safety and addictive potential of these products [23].
Therefore, the aim of this study was to evaluate, through a European cross-sectional survey, the
current level of knowledge about e-cigarettes and THR strategies amongst medical residents/registrars
in public health (MRPH), assessing their knowledge level in the issues of interest and addressing
the need to make fundamental changes in education and training programs, based on the best
evidence available.
2. Materials and Methods
2.1. Population and Sample
The target population of our research—MRPH—corresponds to health professionals (including
non-medical healthcare personnel) enrolled in post-graduate training in public health. Across European
countries, education programs for MRPH differ by curricular pathway, structure, as well as by training
institutions [24]. Indeed, MRPH can be employed in university departments, hospitals, epidemiology
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agencies, and other healthcare institutions. As a consequence of this heterogeneity, the career roles
and responsibilities of MRPH include a vast variety of interventions to reduce risk factors and the
social burden of diseases such as health promotion, health communication, policy and management,
preventive medicine, and epidemiological methods.
For the purposes of this study, an online cross-sectional survey was conducted between April and
October 2018 in a sample of MRPH from the member countries of the European Network of Medical
Residents in Public Health (EuroNet MRPH). The countries associated with EuroNet MRPH during
the study period were Bosnia, Croatia, France, Ireland, Italy, Malta, Moldova, the Netherlands, Poland,
Portugal, Slovenia, Spain, Turkey, and the United Kingdom.
The EuroNet MRPH Board was informed about the nature and protocol of the study. Approval to
carry out this research was granted by the EuroNet MRPH General Assembly and a Working Group
on Electronic Cigarettes and Tobacco Harm Reduction was subsequently formed.
Due to the diversity of the MRPH population in terms of numbers and employment settings across
European countries, it was difficult to identify sample units and gain access to them. For this reason, we
chose a snowball sampling procedure to recruit interview participants, since this method is recognized
as useful for reaching cases in a hard-to-reach uniquely defined network and, according to literature,
it can be utilized to make statistical inferences for examining relationships present in the target
population [25–27]. Specifically, we firstly delivered the self-administered anonymous questionnaire
to all EuroNet MRPH National Commissions, individual members, and national MRPH associations,
where these existed. Each of these were then invited to recruit MRPH, using existing networks or
other means, to participate in the survey. The survey was also uploaded to these associations’ social
media networks.
2.2. Survey Instrument
Data were collected using a self-administered semi-structured online survey, designed at the
primary centre of this investigation (IDIBELL, Preventive Medicine Department, Barcelona, Spain), in
accordance with the literature [14].
The survey was divided into three sections. The first section captured demographic and
professional characteristics of the MRPH, including age, sex, country of residency, residency year,
practice setting, and attendance at any specific training in smoking cessation during residency.
The second section assessed smoking status and habits of the respondents. They were asked to indicate
whether they were current, former or non-smokers. Respondents who were smokers could choose the
smoking product they used (for instance, cigarettes, e-cigarettes, or others). Cigarette smokers were
invited to indicate the number of cigarettes smoked per day and if they were considering quitting.
The third section consisted of 26 items that aimed to assess MRPHs’ knowledge about and attitudes
toward e-cigarettes (i.e., electronic nicotine delivery systems, including heat-not-burn products) and
THR. Attitudes were measured through Likert-type scales, ranging from 1 (low risk) to 10 (high risk),
and stratified into two categories for scoring the perceived health risk of ten smoking products (tobacco
cigarettes, snus, e-cigarettes, nicotine replacement therapy [NRT], non-NRT oral medications) and
components (nicotine, inhaled smoke, carbon monoxide, tobacco, tobacco residue). The perceived
contribution of nicotine to four smoking-related disease outcomes (i.e., smoking-related diseases in
general, lung cancer, cancer in other organs, and atherosclerosis) was assessed as one of “extremely
important”, “very important“, “important”, “unimportant”, and “no contribution”; 20 other items
were used to further investigate MRPHs’ thoughts and knowledge using a series of statements (with
yes/no/do not know or higher/equal/lower/do not know responses). The questions used in the survey and
response options are reported in File S1 (Supplementary Materials).
The questionnaire was delivered to all participants via professional online survey software (Google®
Forms, Google LLC, Mountain View, CA, USA) and was launched in English. All MRPH received an email
inviting them to complete the survey accessible via an embedded Uniform Resource Locator (URL) link.
Clear preliminary statements provided information about the study, and participants provided informed
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consent prior to completing the survey. Involvement was voluntary and no incentives were offered.
MRPH were also informed that all information gathered would be anonymous and that confidentiality
would be maintained by omitting personal identifying information from the analysis.
2.3. Content Validity
Once the survey was delivered to EuroNet MRPH, the Working Group on E-Cigarettes evaluated
the overall acceptability of the questionnaire in terms of length, clarity, and question formats. Based
on its suggestions, minor revisions were made to include changes to questionnaire item wording
and format.
After collection, data were automatically stored in an electronic spreadsheet and were cleaned in
order to reduce the risk of measurement error. Cronbach’s coefficient alpha (α) was measured to gauge
the internal consistency of questions that loaded onto the same factors (i.e., questions related to the
contribution of nicotine to diseases (a), and health risk scores for smoking products and components
(b)). Construct validity was also explored using principal component analysis (PCA), reported in
File S2 (Supplementary Materials).
2.4. Statistical Analysis
The statistical analysis consisted of descriptive and inferential analyses using non-parametric tests.
Non-normal distributions of the underlying data were confirmed using the Kolmogorov-Smirnov test
(p < 0.05 for all). Continuous variables were expressed as median and range; categorical variables were
described as number and percentage. Mann-Whitney U tests (2 groups) or Kruskal-Wallis H tests
(>2 groups) were used to assess differences between medians, and chi-square (χ2) or Fisher’s exact
tests were used to assess differences between categorical variables. All statistical tests were two-tailed
and differences were considered to be statistically significant where p ≤ 0.05. Data were analysed using
Stata v. 10 (Stata Statistical Software: Release 10; StataCorp LP: College Station, TX, USA).
3. Results
Overall, 257 MRPH opened the survey link, of which only one did not agree to participate.
Respondents’ socio-professional characteristics are presented in Table 1.
Approximately half the participants were female (57.4%), with a median age of 30 years, and
were mainly Italian (26.7%), Spanish (16.9%) and Portuguese (16.5%). The most frequent employment
and training setting for MRPH respondents was universities (40.5%), with another 27.8% in hospitals,
14.7% in public health institutes, and 6.7% in the primary care sector. Only 51 (20.1%) MRPH had
attended specific training in smoking cessation during their residency so far. Regarding respondents’
smoking status and habits, 33 (12.9%) self-reported smoking on a regular basis. Cigarettes were the
most commonly used product (69.7%), whereas only 7 (21.2%) current smokers declared they used
e-cigarettes. Overall, one third (33.3%) of current and former smokers came from Italy.
MRPH were asked to score the perceived risk to health of smoking products and components on
a 10-point Likert-type scale ranking from 1 (low risk) to 10 (high risk). Boxplots in Figures 1 and 2, and
Table S1 (Supplementary Materials, File S3) show the results.
Compared with tobacco cigarettes, the perceived risk to health scores of snus and e-cigarettes
were significantly lower (p < 0.001). In addition, risk scores significantly differed for each investigated
smoking product when compared with e-cigarettes, with tobacco cigarettes and snus perceived as
riskier, and NRT and non-NRT oral medications seen as less risky (p < 0.01 for all). Interestingly, no
significant differences in perceived health risk scores for smoking products and components were found
between smokers (current and former) and non-smokers, except for e-cigarettes with smokers declaring
a lower risk (Tables S2 and S3, Supplementary Materials, File S3). Country-based differences in scoring
the risk of smoking products and components were found (Table S4, Supplementary Materials, File S3).
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Table 1. Baseline characteristics of the study population.
Baseline Characteristics (n = 256)
Characteristic * Median (Range) or n (%)
Sex
Male 106 (42.6)
Female 143 (57.4)
Age (years) 30 (23–53)
Country of residency
Croatia 5 (1.9)
France 18 (7.1)
Italy 68 (26.7)
Portugal 42 (16.5)
Slovenia 5 (1.9)
Spain 43 (16.9)
United Kingdom 32 (12.5)
Others 42 (16.5)
Residency year
1st 76 (31.3)
2nd 51 (21.0)
3rd 43 (17.7)
4th 53 (21.8)
5th 9 (3.7)
6th 11 (4.5)
Setting of practice
University 102 (40.5)
Hospital 70 (27.8)
Primary care 17 (6.7)
Public health Institute/Agency 37 (14.7)
Other Health Facilities 26 (10.3)
Attended specific training in smoking cessation during residency
Yes 51 (20.1)
No 203 (79.9)
Smoking status and habits (n = 33)
Smokers
Yes 33 (12.9)
No 198 (77.7)
Former smoker 24 (9.4)
Smoked products §
Cigarettes 23 (69.7)
Number of smoked cigarettes per day 7 (2–25)
E-cigarettes 7 (21.2)
Roll-your-own tobacco 8 (24.2)
Others 7 (21.2)
Considering quitting
Yes 23 (69.7)
No 10 (30.3)
* Number for each item may not add up to total number of study population due to missing values; § Interviewees
could choose more than one item.
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Respondents also reported how important they believed the contribution of nicotine is to some
diseases. Stacked bar-charts in Figure 3 a d Table S5 (Supplem ntary Materials, Fil S3) highlight
that the vast maj rity of respondents believed nicotine to be a significant contributor toward disease,
with 82.2% associating nicotine with all smoking-related disea s, 59.1% indicating an important
contribution to lun cancer, 62.1% to cancer in other organs, and 72.7% consideri it responsible
f r atherosclerosis.
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MRPHs’ responses on e-cigarettes and THR are presented in Table 2. Regarding e-cigarettes, half
the MRPH considered their health risk to be lower than that of tobacco cigarettes (53.1%), but that they
had an equal dependence potential (51.4%). The vast majority (84.9%) agreed that e-cigarettes could
generate addiction.
Table 2. Participants’ responses on e-cigarettes and tobacco harm reduction.
Questions * n (%)
The health risk of nicotine replacement therapies compared to smoking is:
Higher 4 (1.6)
Equal 16 (6.3)
Lower 223 (88.1)
Do not know 10 (4.0)
The health risk of electronic cigarettes compared to smoking is:
Higher 10 (4.0)
Equal 74 (29.4)
Lower 149 (53.1)
Do not know 19 (7.5)
The harmful effect of electronic cigarettes is due to the diethylene glycol:
Yes 57 (22.5)
No 28 (11.1)
Do not know 168 (66.4)
Electronic cigarettes can generate addiction:
Yes 214 (84.9)
No 10 (4.0)
Do not know 28 (11.1)
The dependence potential of electronic cigarettes compared to smoking is:
Higher 26 (10.3)
Equal 130 (51.4)
Lower 65 (25.7)
Do not know 32 (12.6)
Electronic cigarettes are more expensive than normal tobacco:
Yes 83 (32.8)
No 81 (32.0)
Do not know 89 (35.2)
Electronic cigarettes are safer than tobacco:
Yes 111 (44.1)
No 95 (37.7)
Do not know 46 (18.2)
Electronic cigarettes are effective devices for smoking cessation:
Yes 80 (31.7)
No 131 (52.0)
Do not know 41 (16.3)
As a Public Health professional, would you recommend the electronic cigarette as smoking
cessation aid to a patient?
Yes 69 (27.4)
No 161 (63.9)
Do not know 22 (8.7)
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Table 2. Cont.
Questions * n (%)
As a Public Health professional, would you recommend the electronic cigarette to a patient for
reducing the number of smoked cigarettes?
Yes 110 (43.5)
No 118 (46.6)
Do not know 25 (9.9)
Do you think that the concomitant use of electronic cigarettes and tobacco will effectively
reduce the number of smoked cigarettes?
Yes 92 (36.4)
No 115 (45.4)
Do not know 46 (18.2)
Do you think that medical community and healthcare workers should take a position in favor
of the electronic cigarettes?
Yes 73 (29.0)
No 130 (51.6)
Do not know 49 (19.4)
Do you think that electronic cigarettes should be prohibited?
Yes 66 (26.1)
No 143 (56.5)
Do not know 44 (17.4)
Have you heard of modified-risk tobacco?
Yes 62 (24.5)
No 191 (75.5)
The health risk of modified-risk tobacco products compared to smoking is:
Higher 6 (2.4)
Equal 29 (11.6)
Lower 33 (13.3)
Do not know 181 (72.7)
The health risk of modified-risk tobacco products compared to electronic cigarettes is:
Higher 23 (9.2)
Equal 25 (10.0)
Lower 8 (3.2)
Do not know 194 (77.6)
As a Public Health professional, would you recommend modified-risk tobacco products to
reduce tobacco-related problems?
Yes 14 (5.6)
No 59 (23.6)
Do not know 177 (70.8)
* Number for each item may not add up to total number of study population due to missing values.
Only 31.7% respondents felt that e-cigarettes were effective devices for smoking cessation, with a
similar proportion (36.4%) agreeing that concomitant use of e-cigarettes and tobacco effectively reduces
the number of smoked cigarettes. On this point, a large proportion of respondents stated that they
would not recommend e-cigarettes to patients, as either a smoking cessation aid (63.9%) or as a strategy
for reducing the number of smoked cigarettes (46.6%).
Regarding THR strategies, around three-quarters of MRPH admitted to not having heard
about modified-risk tobacco products and not being able to compare their health risk to smoking
and e-cigarettes.
Tables S6–S8 (Supplementary Materials, File S3) show differences in these items by respondents’
smoking status, previous attendance at specific training in smoking cessation, and residency characteristics.
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Internal reliability estimates of the survey suggested a high degree of internal consistency for the
investigated items (Cronbach’s α = 0.79 (a) and 0.75 (b)).
4. Discussion
To our knowledge this is the first Europe-wide study investigating the awareness of healthcare
professionals about e-cigarettes and THR strategies, yielding important findings on the current level of
knowledge amongst a sample of MRPH from countries associated with EuroNet MRPH.
The first interesting finding is the prevalence of smokers in our MRPH respondents, with 12.9%
self-reporting regular use of cigarettes and other tobacco products, and a further 9.4% being former
smokers. Our results displayed a considerably lower rate of self-reported smokers compared with the
European adult population (28%) [28], suggesting the potential influence of a medical background
on smoking habits. However, the observed percentage was much higher than that documented in
physicians in the United States [29]. On this point, accumulating evidence has shown that smoking
trends may not be uniform across different countries, with healthcare workers in some regions still
smoking at fairly high rates, especially in the European context [29] where the highest prevalence
of daily smokers was observed [28]. Overall, the proportion of healthcare professionals who smoke
varies within contexts, also depending on local policies, education and training background, and
risk factors [30]. Similarly, with specific reference to the prevalence of tobacco use among medical
residents/registrars, country-based differences have also been observed, with a Spanish study by
Sánchez et al. [30] finding a prevalence of current and former smokers, respectively, of 6.5% and 5.2%,
while a multicenter survey of MRPH in Italy revealed a smoking prevalence of 20.9% [15].
On the whole, respondents perceived a moderate/high health risk for nicotine, also considering
its impact on smoking-related diseases, including cancer and atherosclerosis. However, they agreed
in ranking NRT risk as lower than that of smoking. It is known that nicotine is a highly addictive
substance, being the most common addiction to a legal drug worldwide.
The overestimation of the harmful effects of nicotine in humans is a widespread and pervasive
belief amongst healthcare workers, perhaps due to the opinion that publicly minimizing the risk
potential of nicotine might convey a false underestimation of smoking-related health risks [14].
Nevertheless, currently available evidence does not suggest that nicotine promotes cancer pathway
activation, and its contribution to cardiovascular disease is lower than that of tobacco smoke [31].
Concerning e-cigarettes, the majority of MRPH considered their health risk and dependence
potential equal to, or lower than, that of tobacco cigarettes, in accordance with general population
beliefs [32], but only one-third ranked them as effective for smoking reduction or cessation. Indeed, the
published literature currently available seems to be insufficient for reliably drawing firm conclusions,
or creating a consensus, on the effectiveness of e-cigarettes as a smoking cessation or harm reduction
tool [4,33,34]. Pertinently, a recently published trial that compared e-cigarettes and NRT in adults
seeking help to quit smoking found that the former showed superiority in one-year abstinence rates [35].
Again, the majority of the surveyed MRPH correctly stated that some alternative nicotine products
(e-cigarettes, snus, NRT, etc.) were safer than smoking cigarettes. These data are also consistent with
users’ beliefs: a recently published nationally representative survey of U.S. adults found that, in the
general population e-cigarettes were seen as less harmful compared to cigarettes, even though the
perceptions of harmfulness varied between the other non-cigarette-tobacco products [36].
Three-quarters of MRPH admitted to never having heard about THR during their medical training or
public health residency. Nevertheless, e-cigarettes, heat-not-burn tobacco devices, snus, and modified-risk
nicotine-containing products continue to attract consumers. For this reason, a paradigm shift is required
in public health sectors, with professionals reappraising THR itself and acknowledging that it is not
risk-free [20].
It is worth underlining that only one-third of respondents considered e-cigarettes an effective
device for smoking cessation and the same proportion agreed with the idea that electronic devices
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should be recommended to patients both as a smoking cessation aid and as a tool for reducing the
number of cigarettes smoked.
Briefly, certain sensitivities toward tobacco control strategies are commonly traceable among
the sampled MRPH, even if respondents’ general opinions on e-cigarettes and THR were discordant,
likely because they might have not received adequate training on tobacco and smoking during their
residency. In fact, only 20.1% of participants attended specific training and this attendance was not
found to be associated with improved knowledge of these topics amongst MRPH.
Overall, our findings suggest a need for educative interventions in public health residency programs
in Europe. We found that MRPHs are not optimally confident with smoking control strategies, despite
being aware of the importance of their role as physicians in anti-tobacco campaigns.
In this respect, public health stakeholders in Europe are promoting a greater awareness of
e-cigarettes and their risks. The present European regulation for electronic nicotine delivery systems
requires that advertising and promotion rules for tobacco products also apply to e-cigarettes, with
packaging that should provide information on toxicity and addictiveness, health warnings, and the list
of all the substances contained—including the exact level of nicotine (which should be at a concentration
level of no more than 20 mg/mL) [37,38]. However, not all European countries are currently complying
with this Tobacco Products Directive. The European Public Health Association recently published a
position statement on the state of the evidence, supporting a precautionary approach to the relative
safety of e-cigarettes compared with traditional cigarettes, and promoting stronger dissemination of
knowledge amongst public health professionals [38].
It is known that assessing medial trainees’ knowledge is a validated method for tailoring
educational programs to the actual training needs of medical professionals [39,40]; this has particular
importance regarding smoking-related topics due to their constant changes. Thus, our study calls
attention to the need for a revision of educational portfolios for European medical trainees in public
health and preventive medicine, introducing “real life” issues, such as smoking/harm reduction and
cessation concepts.
Some potential limitations must be considered in interpreting the findings of this survey. Firstly,
the cross-sectional nature does not allow us to prospectively determine a causal effect of the detected
items. Secondly, possible non-response bias must be considered, since we were unable to assess the
characteristics of MRPH who chose to not participate in the survey. Indeed, the EuroNet Working
Group was unable to determine the total number of the whole European MRPH population, thus a
response rate could not be calculated. For this reason, it is possible that the findings of our study
may not be representative of all European MRPH, and we would strongly encourage further studies
investigating this topic of interest. Thirdly, launching the questionnaire in English might have led
some MRPH from non-English speaking countries to not answer. However, healthcare professionals,
particularly those employed in public health sectors, are expected to speak English. Lastly, whilst the
data revealed some negative perceptions toward e-cigarettes and THR, the responses did not allow for
an exploration of context-related associations with correct/incorrect knowledge or perceptions (for
instance, country-based programs), or for their likely multifactorial nature. Further research should
address these issues.
Despite these limitations, we believe that the aims of this research have been achieved, by
identifying novel information on MRPHs’ perceptions toward e-cigarettes and THR, and highlighting
the need for further studies to better describe determinant factors for future public health professionals’
preparedness in facing challenges that could emerge in their future clinical practice.
5. Conclusions
European MRPH showed a suboptimal level of knowledge about e-cigarettes and THR. This has
important implications, since policymakers and stakeholders should address this gap and re-design
relevant training programs for public health and preventive medicine trainees.
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